Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter

Luo, Guopei; Jin, Kaizhou; Deng, Shengming; He, Cheng; Fan, Zhichao; Gong, Yitao; Qian, Yunzhen; Huang, Qiuyi; Ni, Quanxing; Liu, Chen; Yu, Xianjun

doi:10.1016/j.bbcan.2020.188409

Cited by 169 publications

(119 citation statements)

References 123 publications

Supporting

Mentioning

114

Contrasting

Order By: Relevance

“…Compared with normal tissues, DCBLD2 expression increased in PDAC tissues, which revealed an oncogenic role of DCBLD2. The diagnostic ability of DCBLD2 in tissues was satisfactory, as the AUC value was close to or no less than CA19-9, an established diagnostic biomarker for PDAC (Luo et al, 2020). Extracellular vesicles contain proteins, lipids and RNA from donor cells and can be an attractive source of diagnostic biomarkers for human cancers (Yu et al, 2020).…”

Section: Discussionmentioning

confidence: 96%

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Feng

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Background: Accumulating evidence shows that the elevated expression of DCBLD2 (discoidin, CUB and LCCL domain-containing protein 2) is associated with unfavorable prognosis of various cancers. However, the correlation of DCBLD2 expression value with the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) has not yet been elucidated. Methods: Univariate Cox regression analysis was used to screen robust survival-related genes. Expression pattern of selected genes was investigated in PDAC tissues and normal tissues from multiple cohorts. Kaplan–Meier (K–M) survival curves, ROC curves and calibration curves were employed to assess prognostic performance. The relationship between DCBLD2 expression and immune cell infiltrates was conducted by CIBERSORT software. Biological processes and KEGG pathway enrichment analyses were adopted to clarify the potential function of DCBLD2 in PDAC. Results: Univariate analysis, K–M survival curves and calibration curves indicated that DCBLD2 was a robust prognostic factor for PDAC with cross-cohort compatibility. Upregulation of DCBLD2 was observed in dissected PDAC tissues as well as extracellular vesicles from both plasma and serum samples of PDAC patients. Both DCBLD2 expression in tissue and extracellular vesicles had significant diagnostic value. Besides, DCBLD2 expression was correlated with infiltrating level of CD8+ T cells and macrophage M2 cells. Functional enrichment revealed that DCBLD2 might be involved in cell motility, angiogenesis, and cancer-associated pathways. Conclusion: Our study systematically analyzed the potential diagnostic, prognostic and therapeutic value of DCBLD2 in PDAC. All the findings indicated that DCBLD2 might play a considerably oncogenic role in PDAC with diagnostic, prognostic and therapeutic potential. These preliminary results of bioinformatics analyses need to be further validated in more prospective studies.

show abstract

Section: Discussionmentioning

confidence: 96%

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Feng

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…However, its sensitivity is approximately 80%, 2 with the result that some pancreatic cancer patients are false-negative for CA19-9, and the major challenges include false-negatives for Lewisnegative individuals. 3 The current analysis demonstrated the prognostic significance of the ALBI grade even in the CA19-9-negative group.…”

Section: Presentmentioning

confidence: 49%

ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients

et al. 2021

View full text Add to dashboard Cite

“…All the above-described miRNAs outperformed with respect to the established PDAC biomarker CA 19-9, which levels did not significantly differ between controls and patients. This finding is not surprising, considering its low sensitivity for early tumor diagnosis [50].…”

Section: Discussionmentioning

confidence: 89%

Serum miRNA Profiling for Early PDAC Diagnosis and Prognosis: A Retrospective Study

et al. 2021

View full text Add to dashboard Cite

Background: Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and short survivals have been described in patients with early-stage tumors. Circulating microRNA (miRNA) are an emerging class of suitable biomarkers for PDAC prognosis. Our aim was to identify whether serum miRNA signatures predict survival of early-stage PDAC. Methods: Serum RNA from archival 15 stage I-III PDAC patients and 4 controls was used for miRNAs expression profile (Agilent microarrays). PDAC patients with comparable age, gender, diabetes, jaundice and surgery were classified according to survival: less than 14 months (7/15 pts, group A) and more than 22 months (8/15 pts, group B). Bioinformatic data analysis was performed by two-class Significance Analysis of Microarray (SAM) algorithm. Binary logistic regression analyses considering PDAC diagnosis and outcome as dependent variables, and ROC analyses were also performed. Results: 2549 human miRNAs were screened out. At SAM, 76 differentially expressed miRNAs were found among controls and PDAC (FDR = 0.4%), the large majority (50/76, 66%) of them being downregulated in PDAC with respect to controls. Six miRNAs were independently correlated with early PDAC, and among these, hsa-miR-6821-5p was associated with the best ROC curve area in distinguishing controls from early PDAC. Among the 71 miRNAs differentially expressed between groups A and B, the most significant were hsa-miR-3135b expressed in group A only, hsa-miR-6126 and hsa-miR-486-5p expressed in group B only. Eight miRNAs were correlated with the presence of lymph-node metastases; among these, hsa-miR-4669 is of potential interest. hsa-miR-4516, increased in PDAC and found as an independent predictor of survival, has among its putative targets a series of gens involved in key pathways of cancer progression and dissemination, such as Wnt and p53 signalling pathways. Conclusions: A series of serum miRNAs was identified as potentially useful for the early diagnosis of PDAC, and for establishing a prognosis.

show abstract

Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter

Cited by 169 publications

References 123 publications

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients

Serum miRNA Profiling for Early PDAC Diagnosis and Prognosis: A Retrospective Study

Contact Info

Product

Resources

About